Sam­sung Bi­o­log­ics touts Q2 per­for­mance af­ter ex­pand­ing deals with big phar­mas

CD­MO Sam­sung Bi­o­log­ics said its rev­enue jumped 33% in the sec­ond quar­ter, dur­ing which it an­nounced deals with ma­jor drug­mak­ers like Pfiz­er and No­var­tis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER